Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer
Clinical trial NCT00705315 · COMPLETED
Trial details
- NCT number
- NCT00705315
- Sponsor
- Hellenic Oncology Research Group
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2008-05-01
- Primary completion
- 2010-06-01
- Enrollment
- 46
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.